Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

66.25 +0.37 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
61 62 Next >
3 Alzheimer's Therapy Stocks to Invest in
Alzheimer's treatments could make a big winner of these stocks. 
Via The Motley Fool
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
From AstraZeneca
Via Business Wire
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical stock combines strong financials with an above-average dividend. 
Via The Motley Fool
This Growth Stock Rose Last Week. Is It Still a Buy?
Illumina is the dominant player in gene sequencing. 
Via The Motley Fool
7 Stocks to Buy When There’s Blood in the Streets
For investors looking for high-quality stocks to buy when there is blood in the streets, there happen to be plenty of companies to pick. 
Via InvestorPlace
2 Top Healthcare Stocks to Buy for the Long Haul
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
AVEO stock jumped on the news that LG Chem will pay $15/share for Aveo Oncology and make it the centerpiece of a new oncology division. 
Via InvestorPlace
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
From Ikena Oncology, Inc.
Via GlobeNewswire
Is This Monster Stock on the Verge of a Home Run?
Ultomiris was just approved in the European Union to treat patients with generalized myasthenia gravis. 
Via The Motley Fool
2 Top Biotech Stocks to Buy Right Now
Healthcare is a reliable sector of the economy for those looking to create wealth over the long haul. 
Via The Motley Fool
3 Incredibly Cheap Blue Chip Stocks to Buy Right Now
It's time to buy the dip in these blue chip stocks. 
Via The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less Than $100
There's no need to break the bank to buy quality stocks. 
Via The Motley Fool
Is Seagen Stock a Buy Now?
It's growing faster than competitors, but headwinds might soon bog it down. 
Via The Motley Fool
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
From Alexion
Via Business Wire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
Exposures COVID-19
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
Via Benzinga
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
Reuters US-China Chip War: KLA Relaxes Chip Supply To China 
Via Benzinga
AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial
AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. 
Via Benzinga
Have $2,000? 2 Market Crash-Ready Stocks to Buy
These two big pharma stocks have what it takes to bounce back. 
Via The Motley Fool
2 Healthcare Stocks That Could Help Make You a Fortune
If given enough time, these two stocks can do the heavy lifting in building wealth for you. 
Via The Motley Fool
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
Exposures Financial Legal Supply Chain
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
Will Chart Analysts Notice Bad Omen on AstraZeneca's Chart
If history is any guide, there may be trouble ahead for shares of AstraZeneca (NASDAQ:AZN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the... 
Via Benzinga
Why Is LogicBio (LOGC) Stock Up 600% Today?
LogicBio (LOGC) stock is seeing massive gains on Monday following news that AstraZeneca (AZN) subsidiary Alexion is acquiring the company. 
Via InvestorPlace
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. 
Via Benzinga
Why LogicBio Therapeutics Stock Is Soaring Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN) subsidiary Alexion for $2.07 per share.  
Via Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
Via Benzinga
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
From Alexion
Via Business Wire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.